Literature DB >> 20516174

Production of SV40-derived vectors.

David S Strayer, Christine Mitchell, Dawn A Maier, Carmen N Nichols.   

Abstract

Recombinant simian virus 40 (rSV40)-derived vectors are particularly useful for gene delivery to bone marrow progenitor cells and their differentiated derivatives, certain types of epithelial cells (e.g., hepatocytes), and central nervous system neurons and microglia. They integrate rapidly into cellular DNA to provide long-term gene expression in vitro and in vivo in both resting and dividing cells. Here we describe a protocol for production and purification of these vectors. These procedures require only packaging cells (e.g., COS-7) and circular vector genome DNA. Amplification involves repeated infection of packaging cells with vector produced by transfection. Cotransfection is not required in any step. Viruses are purified by centrifugation using discontinuous sucrose or cesium chloride (CsCl) gradients and resulting vectors are replication-incompetent and contain no detectable wild-type SV40 revertants. These approaches are simple, give reproducible results, and may be used to generate vectors that are deleted only for large T antigen (Tag), or for all SV40-coding sequences capable of carrying up to 5 kb of foreign DNA. These vectors are best applied to long-term expression of proteins normally encoded by mammalian cells or by viruses that infect mammalian cells, or of untranslated RNAs (e.g., RNA interference). The preparative approaches described facilitate application of these vectors and allow almost any laboratory to exploit their strengths for diverse gene delivery applications.

Entities:  

Mesh:

Year:  2010        PMID: 20516174     DOI: 10.1101/pdb.prot5436

Source DB:  PubMed          Journal:  Cold Spring Harb Protoc        ISSN: 1559-6095


  1 in total

1.  Cre Recombinase Mediates the Removal of Bacterial Backbone to Efficiently Generate rSV40.

Authors:  Xiaoxia Shi; Matthew Ryan Ykema; Jaco Hazenoot; Lysbeth Ten Bloemendaal; Irene Mancini; Machteld Odijk; Peter de Haan; Piter J Bosma
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-27       Impact factor: 6.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.